LEOLIGIN DERIVATIVES AS SMOOTH MUSCLE CELL PROLIFERATION INHIBITORS

摘要

The invention relates to compounds of formula (II) for use as drugs that selectively inhibit the proliferation of SMCs in comparison with the proliferation of ECs: formula (II), wherein R1 to R6 are selected from -H, -F, -CH3, -CF3, -CF2CH3, -OCH3, -COCH3, -C4H9, -COOC2H5, and -C6H5 or two vicinal groups from R1 to R6 are of such a nature and are connected to each other in such a way that said vicinal groups form a saturated or unsaturated carbocyclic ring together with the two carbon atoms to which said vicinal groups are bonded; R7 is selected from OH, allyloxy, propargyloxy, 2,2-dimethylpropanoyloxy (pivaloyloxy), butanoyloxy, 3-methylbutanoyloxy, 2-butenoyloxy, 2-methyl-2-butenoyloxy, 3-methyl-2-butenoyloxy, isopentanoyloxy, 2-ethylbutanoyloxy, 3,3-dimethyl-butanoyloxy, cyclopropylcarbonyloxy, cyclobutylcarbonyloxy, cyclopentylcarbonyloxy, cyclopentenylcarbonyloxy, cyclohexylcarbonyloxy, cyclohexenylcarbonyloxy, adamantylethanoyloxy, 3-phenylpropenoyloxy (cinnamyloyloxy), 2-methylbenzoyloxy, and naphthoyloxy; and one or more ring carbon atoms are possibly replaced by heteroatoms in ring A and/or ring B; wherein the compounds of formula (II) are selected from compounds that are obtained by corresponding combination of groups R1 to R7 and that inhibit the proliferation of SMCs at least 50% more strongly than the proliferation of ECs; and a new production method for such compounds of formula (II).